China Antibody-B: SN1011 New Drug Research Application Approved.

Guide: SN1011 is a third-generation reversible co-priced Bruton tyrosine kinase ("BTK") inhibitor.
, China Antibody-B announced that on August 27, 2020, the application for a new drug for SN1011, an autoimmune disease, has been approved by China's State Drug Administration.
The approval of the new drug research application will allow the company to start a comprehensive clinical research and development program in China targeting systemic lupus erythematosus ("systemic lupus"), which is also the primary target adaptation in the company's SN1011 clinical research and development program.
plans to begin Phase I clinical trials in China in the near future.
SN1011 is the company's third generation of reversible co-priced Bruton tyrosine kinase ("BTK") inhibitors designed to be more selective and superior in the long-term treatment of systemic lupus erythematosus, rheumatoid arthritis, herpes, multiple sclerosis and other autoimmune diseases.
SN1011 has a differentiated advantage over existing BTK inhibitors such as Erudini in the current market in terms of targeting selectivity and affinity.
.